News

Recent updates and announcements

on August 12, 2019

Biogazelle announced today that it has been awarded €499K in funding from European commission under the Horizon 2020 - Research and Innovation Framework Programme. For the purposes of this investigation, …

Read more

on June 5, 2019

Biogazelle CSO and Professor at Ghent University Jo Vandesompele, will deliver a presentation at the Twist Biosciences workshop "Believe in Better: Leading the Way in Target Enrichment" during ESHG 2019 on Monday, …

Read more

on April 25, 2018

In March 2013, we announced a completely new visual identity and matching website, heralding a new phase in our growth as a young and dynamic company. Today, it is exactly …

Read more

on January 15, 2018

Bio Analytical Research Corporation (BARC), the global central laboratory division of Cerba HealthCare, today announces that Biogazelle will join the pool of expert laboratories they consistently collaborate with. BARC is …

Read more

on April 18, 2017

This month, Biogazelle launches a novel and unique application: mRNA sequencing on human plasma. mRNA sequencing on plasma – or other body fluids – has not yet been offered by …

Read more

on March 6, 2017

Jo, congratulations with this amazing achievement of your R&D team at Biogazelle. Tell us, why are you so excited about the work you have done? What we offer today is …

Read more

on March 24, 2016

The 'Survival Associated Mitochondrial Melanoma Specific ONcogenic RNA' is a long non-coding RNA that is specifically expressed in malignant melanoma cells, and not in other normal human cells or other …

Read more

on November 5, 2015

Exiqon A/S (NASDAQ OMX: EXQ), a leading provider of flexible solutions for RNA analysis, today announced the impressive results of a comparative study on technologies for functional knockdown. The study …

Read more

on October 20, 2015

MARLBOROUGH, Mass., Oct. 20, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology …

Read more

on October 15, 2015

Biogazelle NV today announced a research-stage collaboration with Isis Pharmaceuticals in which they will identify and validate novel targets to treat colon, liver and lung cancer, diseases with clear unmet …

Read more